3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Conditions
Breast Neoplasms
8
Sarcopenia
2
Prostatic Neoplasms
2
Obesity
2
Melanoma
2
Malnutrition
2
Colorectal Neoplasms
2
Breast Carcinoma In Situ
2
Wound Infection
1
Weight Loss
1
Surgical Wound Infection
1
Skin Neoplasms
1
Psoriasis
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Precancerous Conditions
1
Postoperative Complications
1
Polycystic Ovary Syndrome
1
Phagocyte Bactericidal Dysfunction
1
Pain
1
Paget's Disease, Mammary
1
Osteoarthritis
1
Olfaction Disorders
1
Neoplasms
1
Neoplasm, Residual
1
Mandibular Neoplasms
1
Lymphoma, Follicular
1
Lipid Metabolism Disorders
1
Huntington Disease
1
Fatigue
1
Diabetes Mellitus
1
Interventions
Adalimumab
13
Etanercept
8
Methotrexate
7
Rituximab
6
Abatacept
6
tocilizumab
5
golimumab
5
tofacitinib
4
olokizumab
4
Certolizumab Pegol
4
Tumor Necrosis Factor Inhibitors
3
Infliximab
3
Saline Solution
2
Antirheumatic Agents
2
upadacitinib
1
secukinumab
1
sarilumab
1
mavrilimumab
1
baricitinib
1
Vitamin D
1
Vaccines
1
TACI receptor-IgG Fc fragment fusion protein
1
Syringes
1
Sulfasalazine
1
Sodium Chloride
1
Radioimmunodetection
1
RC-18
1
Pharmaceutical Preparations
1
Lysine Acetyltransferase 5
1
Leflunomide
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Arthritis, Rheumatoid
×
Docosahexaenoic Acids
×
Clear all
NCT01351805
2025-12-03
VITAL
Brigham and Women's Hospital
Phase NA
Completed
25,871 enrolled
15 charts